Phase II study of docetaxel and trametinib in patients with KRAS mutation positive recurrent non-small cell lung cancer (NSCLC) (SWOG S1507, NCT-02642042).

Shirish M Gadgeel Jieling Miao Jonathan W Riess James Moon Philip C Mack Gregory J Gerstner Timothy F Burns Asma Taj Wallace L Akerley Konstantin H Dragnev Noel Laudi Mary W Redman Jhanelle E Gray David R Gandara Karen Kelly

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

RRs were significantly improved in the overall population. Contrary to pre-clinical studies, the combination showed no improvement in efficacy in G12C patients. Co-mutations may influence therapeutic efficacy of KRAS directed therapies and are worthy of further evaluation.

Keyphrases

phase ii study
end stage renal disease
newly diagnosed
chronic kidney disease
ejection fraction
small cell lung cancer
locally advanced
prognostic factors
squamous cell carcinoma
open label
peritoneal dialysis
study protocol
clinical trial
tyrosine kinase
patient reported outcomes